Exploring treatment strategies for paroxysmal nocturnal hemoglobinuria: an overview of registered clinical trials

References

• Brodsky RA. Paroxysmal nocturnal hemoglobinuria. Blood. 2014;124(18):2804–2811. doi:10.1182/blood-2014-02-522128.
   PubMed Web of Science ®Google Scholar
• Hillmen P, Young NS, Schubert J, et al. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med. 2006;355(12):1233–1243. doi:10.1056/NEJMoa061648.
   PubMed Web of Science ®Google Scholar
• Hillmen P, Muus P, Dührsen U, et al. Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria. Blood. 2007;110(12):4123–4128. doi:10.1182/blood-2007-06-095646.
   PubMed Web of Science ®Google Scholar
• Notaro R, Sica M. C3-mediated extravascular hemolysis in PNH on eculizumab: mechanism and clinical implications. Semin Hematol. 2018;55:130–135.
   PubMed Web of Science ®Google Scholar
• Risitano AM, Marotta S, Ricci P, et al. Anti-complement treatment for paroxysmal nocturnal hemoglobinuria: time for proximal complement inhibition? A position paper From the SAAWP of the EBMT. Front Immunol. 2019;10:1157. doi:10.3389/fimmu.2019.01157.
   PubMed Web of Science ®Google Scholar
• Notaro R, Luzzatto L. Breakthrough hemolysis in PNH with proximal or terminal complement inhibition. N Engl J Med. 2022;387(2):160–166. doi:10.1056/NEJMra2201664.
   PubMed Web of Science ®Google Scholar
• Dmytrijuk A, Robie-Suh K, Cohen MH, et al. FDA report: eculizumab (soliris) for the treatment of patients with paroxysmal nocturnal hemoglobinuria. Oncologist. 2008;13(9):993–1000. doi:10.1634/theoncologist.2008-0086.
   PubMed Web of Science ®Google Scholar
• Brodsky RA, Young NS, Antonioli E, et al. Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria. Blood. 2008;111(4):1840–1847. doi:10.1182/blood-2007-06-094136.
   PubMed Web of Science ®Google Scholar
• SHEPHERD: safety in hemolytic PNH patients treated with eculizumab: a multi-center open-label research design [Internet]. Clinicaltrials.gov. U.S. National Institutes of Health. 2023. https://clinicaltrials.gov/study/NCT00130000
   Google Scholar
• Kanakura Y, Ohyashiki K, Shichishima T, et al. Safety and efficacy of the terminal complement inhibitor eculizumab in japanese patients with paroxysmal nocturnal hemoglobinuria: the AEGIS clinical trial. Int J Hematol. 2011;93(1):36–46. doi:10.1007/s12185-010-0748-9.
   PubMed Web of Science ®Google Scholar
• Phase II clinical study of eculizumab (h5G1.1-mAb) in hemolytic Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients [Internet]. Clinicaltrials.gov. U. S. National Institutes of Health. 2024. https://clinicaltrials.gov/study/NCT01192399.
   Google Scholar
• Kanakura Y, Ohyashiki K, Shichishima T, et al. Long-term efficacy and safety of eculizumab in japanese patients with PNH: AEGIS trial. Int J Hematol. 2013;98(4):406–416. doi:10.1007/s12185-013-1404-y.
   PubMed Web of Science ®Google Scholar
• Phase II clinical study of eculizumab (h5G1.1-mAb) in hemolytic Paroxysmal Nocturnal Hemoglobinuria (PNH) patients: extension Study to C07-001 Protocol [Internet]. Clinicaltrials.gov. U. S. National Institutes of Health. 2023. https://clinicaltrials.gov/study/NCT01194804.
   Google Scholar
• Open label extension study of eculizumab in patients with transfusion dependent PNH [Internet]. Clinicaltrials.gov. U. S. National Institutes of Health. 2023. https://clinicaltrials.gov/study/NCT00122317.
   Google Scholar
• Reiss UM, Schwartz J, Sakamoto KM, et al. Efficacy and safety of eculizumab in children and adolescents with paroxysmal nocturnal hemoglobinuria. Pediatr Blood Cancer. 2014;61(9):1544–1550. doi:10.1002/pbc.25068.
   PubMed Web of Science ®Google Scholar
• An open-label multi-center study of eculizumab in children and adolescents with a diagnosis of paroxysmal nocturnal hemoglobinuria [Internet]. Clinicaltrials.gov. U. S. National Institutes of Health. 2023. https://clinicaltrials.gov/study/NCT00867932.
   Google Scholar
• Open-label, multicenter study to assess the efficacy, safety, pharmacokinetics, pharmacodynamics, and immunogenicity of eculizumab in complement inhibitor treatment naïve adult participants with Paroxysmal Nocturnal Hemoglobinuria (PNH) in China [Internet]. Clinicaltrials.gov. U. S. National Institutes of Health. 2023. https://clinicaltrials.gov/study/NCT05886244.
   Google Scholar
• Nishimura J, Yamamoto M, Hayashi S, et al. Genetic variants in C5 and poor response to eculizumab. N Engl J Med. 2014;370(7):632–639. doi:10.1056/NEJMoa1311084.
   PubMed Web of Science ®Google Scholar
• McKeage K. Ravulizumab: first global approval. Drugs. 2019;79(3):347–352. doi:10.1007/s40265-019-01068-2.
   PubMed Web of Science ®Google Scholar
• Stern RM, Connell NT. Ravulizumab: a novel C5 inhibitor for the treatment of paroxysmal nocturnal hemoglobinuria. Ther Adv Hematol. 2019;10:2040620719874728. doi:10.1177/2040620719874728.
   Web of Science ®Google Scholar
• An open-label, intrapatient, dose-escalation study to evaluate the safety, tolerability, efficacy, pharmacokinetics, and pharmacodynamics of ALXN1210 administered intravenously to patients with paroxysmal nocturnal hemoglobinuria [Internet]. Clinicaltrials.gov. U. S. National Institutes of Health. 2023. https://clinicaltrials.gov/study/NCT02598583.
   Google Scholar
• Röth A, Rottinghaus ST, Hill A, et al. Ravulizumab (ALXN1210) in patients with paroxysmal nocturnal hemoglobinuria: results of 2 phase 1b/2 studies. Blood Adv. 2018;2(17):2176–2185. doi:10.1182/bloodadvances.2018020644.
   PubMed Web of Science ®Google Scholar
• Phase A, open-label 2, multiple ascending dose study to evaluate the efficacy, safety, tolerability, immunogenicity, pharmacokinetics, and pharmacodynamics of ALXN1210 administered intravenously to patients with paroxysmal nocturnal hemoglobinuria [Internet]. Clinicaltrials.gov. U. S. National Institutes of Health. 2023. https://clinicaltrials.gov/study/NCT02605993.
   Google Scholar
• Kulasekararaj AG, Hill A, Rottinghaus ST, et al. Ravulizumab (ALXN1210) vs eculizumab in C5-inhibitor-experienced adult patients with PNH: the 302 study. Blood. 2019;133(6):540–549. doi:10.1182/blood-2018-09-876805.
   PubMed Web of Science ®Google Scholar
• Lee JW, Sicre de Fontbrune F, Wong Lee Lee L, et al. Ravulizumab (ALXN1210) vs eculizumab in adult patients with PNH naive to complement inhibitors: the 301 study. Blood. 2019;133(6):530–539. doi:10.1182/blood-2018-09-876136.
   PubMed Web of Science ®Google Scholar
• Schrezenmeier H, Kulasekararaj A, Mitchell L, et al. One-year efficacy and safety of ravulizumab in adults with paroxysmal nocturnal hemoglobinuria naïve to complement inhibitor therapy: open-label extension of a randomized study. Ther Adv Hematol. 2020;11:2040620720966137.
   Web of Science ®Google Scholar
• Brodsky RA, Peffault de Latour R, Rottinghaus ST, et al. Characterization of breakthrough hemolysis events observed in the phase 3 randomized studies of ravulizumab versus eculizumab in adults with paroxysmal nocturnal hemoglobinuria. Haematologica. 2021;106(1):230–237. doi:10.3324/haematol.2019.236877.
   PubMed Web of Science ®Google Scholar
• Schwartz CE, Stark RB, Borowiec K, et al. Norm-based comparison of the quality-of-life impact of ravulizumab and eculizumab in paroxysmal nocturnal hemoglobinuria. Orphanet J Rare Dis. 2021;16(1):389. doi:10.1186/s13023-021-02016-8.
   PubMed Web of Science ®Google Scholar
• A Phase 3, Randomized, Open-Label, Active-Controlled Study of ALXN1210 Versus Eculizumab in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Eculizumab [Internet]. Clinicaltrials.gov. U. S. National Institutes of Health. 2023. https://clinicaltrials.gov/study/NCT03056040.
   Google Scholar
• Lee JW, Kulasekararaj AG. Ravulizumab for the treatment of paroxysmal nocturnal hemoglobinuria. Expert Opin Biol Ther. 2020;20(3):227–237. doi:10.1080/14712598.2020.1725468.
   PubMed Web of Science ®Google Scholar
• Peipert JD, Kulasekararaj AG, Gaya A, et al. Patient preferences and quality of life implications of ravulizumab (every 8 weeks) and eculizumab (every 2 weeks) for the treatment of paroxysmal nocturnal hemoglobinuria. PLoS One. 2020;15(9):e0237497. doi:10.1371/journal.pone.0237497.
   PubMed Web of Science ®Google Scholar
• Yenerel MN, Sicre de Fontbrune F, Piatek C, et al. Phase 3 study of subcutaneous Versus intravenous ravulizumab in eculizumab-Experienced adult patients with PNH: primary analysis and 1-Year Follow-Up. Adv Ther. 2023;40(1):211–232. doi:10.1007/s12325-022-02339-3.
   PubMed Web of Science ®Google Scholar
• Kulasekararaj A, Brodsky R, Kulagin A, et al. Biosimilars in rare diseases: a focus on paroxysmal nocturnal hemoglobinuria. Haematologica. 2023;108(5):1232–1243. doi:10.3324/haematol.2022.281562.
   PubMed Web of Science ®Google Scholar
• Chow V, Pan J, Chien D, et al. A randomized, double-blind, single-dose, three-arm, parallel group study to determine pharmacokinetic similarity of ABP 959 and eculizumab (soliris(®)) in healthy male subjects. Eur J Haematol. 2020;105:66–74.
   PubMed Web of Science ®Google Scholar
• Randomized A. Double-blind, active-controlled phase 3 study evaluating the efficacy and safety of ABP 959 compared with eculizumab in adult subjects with Paroxysmal Nocturnal Hemoglobinuria (PNH) [Internet]. Clinicaltrials.gov. U. S. National Institutes of Health. 2023. https://www.clinicaltrials.gov/study/NCT03818607.
   Google Scholar
• Kulasekararaj A, Lanza F, Arvanitakis A, et al. Efficacy and safety of biosimilar candidate ABP 959 As compared with eculizumab reference product in paroxysmal nocturnal hemoglobinuria. Blood. 2022;140(Supplement 1):8660–8662. doi:10.1182/blood-2022-166722.
   Google Scholar
• Gusarova V, Degterev M, Lyagoskin I, et al. Analytical and functional similarity of biosimilar elizaria® with eculizumab reference product. J Pharm Biomed Anal. 2022;220:115004.
   PubMed Web of Science ®Google Scholar
• Kim H, Hong E, Lee J, et al. Characterization for the similarity assessment between proposed biosimilar SB12 and eculizumab reference product using a state-of-the-Art analytical method. BioDrugs. 2023;37(4):569–581. doi:10.1007/s40259-023-00591-9.
   PubMed Web of Science ®Google Scholar
• Weyne J, Ni Y, DelGizzi R, et al. A randomized, Double-Blind, Placebo-Controlled phase 1 study of the pharmacokinetics and pharmacodynamics of REGN3918, a human antibody Against complement factor C5, in healthy volunteers. Blood. 2018;132(Supplement 1):1039–1039. doi:10.1182/blood-2018-99-112262.
   PubMed Web of Science ®Google Scholar
• An open-label, single arm study to evaluate the efficacy and safety of REGN3918 in patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) who are complement inhibitor-naive or have not recently received complement inhibitor therapy [Internet]. Clinicaltrials.gov. U. S. National Institutes of Health. 2023. https://www.clinicaltrials.gov/study/NCT03946748.
   Google Scholar
• Jang J-H, Weyne J, Chaudhari U, et al. Pozelimab, a human monoclonal antibody Against complement factor C5, provided inhibition of intravascular hemolysis in patients with paroxysmal nocturnal hemoglobinuria. Blood. 2021;138(Supplement 1):1128–1128. doi:10.1182/blood-2021-146178.
   Google Scholar
• Hoy SM. Pozelimab: first approval. Drugs. 2023;83(16):1551–1557. doi:10.1007/s40265-023-01955-9.
   PubMed Web of Science ®Google Scholar
• Badri P, Jiang X, Borodovsky A, et al. Pharmacokinetic and pharmacodynamic properties of cemdisiran, an RNAi therapeutic targeting complement component 5, in healthy subjects and patients with paroxysmal nocturnal hemoglobinuria. Clin Pharmacokinet. 2021;60(3):365–378. doi:10.1007/s40262-020-00940-9.
   PubMed Web of Science ®Google Scholar
• A phase 1/2 single-ascending and multiple-ascending dose, safety, tolerability, pharmacokinetics, and pharmacodynamics study of subcutaneously administered ALN-CC5 in healthy adult volunteers and patients with paroxysmal nocturnal hemoglobinuria [Internet]. Clinicaltrials.gov. U. S. National Institutes of Health. 2023. https://clinicaltrials.gov/study/NCT02352493.
   Google Scholar
• Gaya A, Munir T, Urbano-Ispizua A, et al. Results of a phase 1/2 study of cemdisiran in healthy subjects and patients with paroxysmal nocturnal hemoglobinuria. EJHaem. 2023;4(3):612–624. doi:10.1002/jha2.748.
   PubMedGoogle Scholar
• A randomized, open-label, two-arm study to evaluate the safety, efficacy, and pharmacodynamic effects of pozelimab and cemdisiran combination treatment in patients with paroxysmal nocturnal hemoglobinuria who have received pozelimab monotherapy [Internet]. Clinicaltrials.gov. U. S. National Institutes of Health. 2023. https://www.clinicaltrials.gov/study/NCT04811716.
   Google Scholar
• Jang JH, Wong R, Pavani R, et al. A phase 2, randomized trial evaluating the safety and efficacy of pozelimab and cemdisiran in patients with paroxysmal nocturnal hemoglobinuria. Blood. 2022;140(Supplement 1):8172–8173. doi:10.1182/blood-2022-163236.
   Google Scholar
• Single arm A, open-label study to assess the safety, efficacy, and pharmacodynamic effects of pozelimab and cemdisiran combination therapy in patients with paroxysmal nocturnal hemoglobinuria who switch from eculizumab therapy [Internet]. Clinicaltrials.gov. U. S. National Institutes of Health. 2023. https://clinicaltrials.gov/study/NCT04888507
   Google Scholar
• Kelly R, Houghton N, Munir T, et al. P797: a phase 2, Open-Label study evaluating The safety And efficacy Of combination pozelimab And cemdisiran therapy In patients With paroxysmal nocturnal hemoglobinuria who switch From eculizumab. Hemasphere. 2023;7(S3):e6873083. doi:10.1097/01.HS9.0000970092.68730.83.
   Google Scholar
• A randomized, open-label, C5 inhibitor-controlled study to evaluate the efficacy and safety of pozelimab and cemdisiran combination therapy in patients with paroxysmal nocturnal hemoglobinuria who are complement inhibitor treatment-naive or have not recently received complement inhibitor therapy [Internet]. Clinicaltrials.gov. U. S. National Institutes of Health. 2023. https://clinicaltrials.gov/study/NCT05133531.
   Google Scholar
• An open-label extension study to evaluate the long-term safety, tolerability, and efficacy of pozelimab and cemdisiran combination therapy in patients with Paroxysmal Nocturnal Hemoglobinuria [Internet]. Clinicaltrials.gov. U. S. National Institutes of Health. 2023. https://www.clinicaltrials.gov/study/NCT05744921.
   Google Scholar
• An adaptive phase I/II study to assess safety, efficacy, pharmacokinetics and pharmacodynamics of crovalimab in healthy volunteers and patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) [Internet]. Clinicaltrials.gov. U. S. National Institutes of Health. 2023. https://www.clinicaltrials.gov/study/NCT03157635.
   Google Scholar
• Röth A, Nishimura J-I, Nagy Z, et al. The complement C5 inhibitor crovalimab in paroxysmal nocturnal hemoglobinuria. Blood. 2020;135(12):912–920. doi:10.1182/blood.2019003399.
   PubMed Web of Science ®Google Scholar
• Nishimura J-I, Usuki K, Ramos J, et al. Crovalimab for treatment of patients with paroxysmal nocturnal haemoglobinuria and complement C5 polymorphism: subanalysis of the phase 1/2 COMPOSER study. Br J Haematol. 2022;198(3):e46–e50. doi:10.1111/bjh.18274.
   PubMed Web of Science ®Google Scholar
• A phase III, multicenter, single arm study evaluating the efficacy, safety, pharmacokinetics, and pharmacodynamics of crovalimab in patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Not Previously Treated With Complement Inhibition [Internet]. Clinicaltrials.gov. U. S. National Institutes of Health. 2023. https://www.clinicaltrials.gov/study/NCT04654468.
   Google Scholar
• Liu H, Xia L, Weng J, et al. Efficacy and safety of the C5 inhibitor crovalimab in complement inhibitor-naive patients with PNH (COMMODORE 3): A multicenter, phase 3, single-arm study. Am J Hematol. 2023;98(9):1407–1414.
   PubMed Web of Science ®Google Scholar
• A phase III, randomized, open-label, active-controlled, multicenter study evaluating the safety, pharmacokinetics, pharmacodynamic and efficacy of crovalimab versus eculizumab in patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Complement Inhibitors. Clinicaltrials.gov. U. S. National Institutes of Health. 2023. https://www.clinicaltrials.gov/study/NCT04432584
   Google Scholar
• A phase III, randomized, open-label, active-controlled, multicenter study evaluating the efficacy and safety of crovalimab versus eculizumab in patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) not previously treated with complement inhibitors. [Internet]. Clinicaltrials.gov. U. S. National Institutes of Health. 2023. https://www.clinicaltrials.gov/study/NCT04434092.
   Google Scholar
• An open-label proof of concept study to assess the efficacy, safety and pharmacokinetics of LFG316, an anti-C5 monoclonal antibody in patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) [Internet]. Clinicaltrials.gov. U. S. National Institutes of Health. 2023. https://www.clinicaltrials.gov/study/NCT02534909.
   Google Scholar
• Nishimura J, Ando K, Masuko M, et al. Tesidolumab (LFG316) for treatment of C5-variant patients with paroxysmal nocturnal hemoglobinuria. haematol. 2022;107(6):1483–1488. doi:10.3324/haematol.2020.265868.
   PubMed Web of Science ®Google Scholar
• Gorman DM, Lee J, Payne CD, et al. Chemical synthesis and characterisation of the complement C5 inhibitory peptide zilucoplan. Amino Acids. 2021;53(1):143–147. doi:10.1007/s00726-020-02921-5.
   PubMed Web of Science ®Google Scholar
• A phase 2 multicenter, open-label, uncontrolled study to evaluate the safety, tolerability, efficacy, pharmacokinetics, and pharmacodynamics of RA101495 in subjects with paroxysmal nocturnal hemoglobinuria who have an inadequate response to eculizumab [Internet]. Clinicaltrials.gov. U. S. National Institutes of Health. 2023. https://clinicaltrials.gov/study/NCT03030183.
   Google Scholar
• Phase 2 multicenter, open-label, uncontrolled study to evaluate the safety, tolerability, efficacy, pharmacokinetics, and pharmacodynamics of RA101495 in subjects with Paroxysmal Nocturnal Hemoglobinuria [Internet]. Clinicaltrials.gov. U. S. National Institutes of Health. 2023. https://clinicaltrials.gov/study/NCT03078582.
   Google Scholar
• Kulasekararaj AG, Lehtinen A-E, Forsyth C, et al. Phase II trials of zilucoplan in paroxysmal nocturnal hemoglobinuria. haematol. 2023;109(3):929–935. doi:10.3324/haematol.2022.281780.
   Web of Science ®Google Scholar
• Schols S, Nunn MA, Mackie I, et al. Successful treatment of a PNH patient non-responsive to eculizumab with the novel complement C5 inhibitor coversin (nomacopan). Br J Haematol. 2020;188(2):334–337. doi:10.1111/bjh.16305.
   PubMed Web of Science ®Google Scholar
• Investigational product; coversin. phase III safety and efficacy in three-part, two-arm, randomised open label evaluation in patients with Paroxysmal Nocturnal Haemoglobinuria (PNH) [Internet]. Clinicaltrials.gov. U. S. National Institutes of Health. 2023. https://clinicaltrials.gov/study/NCT03588026.
   Google Scholar
• Lee JW, Brodsky RA, Nishimura J-I, et al. The role of the alternative pathway in paroxysmal nocturnal hemoglobinuria and emerging treatments. Expert Rev Clin Pharmacol. 2022;15:851–861.
   PubMed Web of Science ®Google Scholar
• Hoy SM. Pegcetacoplan: first approval. Drugs. 2021;81(12):1423–1430. doi:10.1007/s40265-021-01560-8.
   PubMed Web of Science ®Google Scholar
• Wong RSM, Pullon HWH, Amine I, et al. Inhibition of C3 with pegcetacoplan results in normalization of hemolysis markers in paroxysmal nocturnal hemoglobinuria. Ann Hematol. 2022;101(9):1971–1986. doi:10.1007/s00277-022-04903-x.
   PubMed Web of Science ®Google Scholar
• de Castro C, Grossi F, Weitz IC, et al. C3 inhibition with pegcetacoplan in subjects with paroxysmal nocturnal hemoglobinuria treated with eculizumab. Am J Hematol. 2020;95:1334–1343.
   PubMed Web of Science ®Google Scholar
• A phase 3, randomized, multicenter, open-label, controlled study to evaluate the efficacy and safety of pegcetacoplan in patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) [Internet]. Clinicaltrials.gov. U.S.National Institutes of Health. 2023. https://clinicaltrials.gov/study/NCT04085601.
   Google Scholar
• del Pozo Martín Y. 2021 ASH annual meeting Lancet Haematol. 2022;9:p. e92–e93.
   Google Scholar
• A phase III, randomized, multi-center, open-label, active-comparator controlled study to evaluate the efficacy and safety of APL-2 in patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) [Internet]. Clinicaltrials.gov. U. S. National Institutes of Health. 2023. https://clinicaltrials.gov/study/NCT03500549.
   Google Scholar
• Hillmen P, Szer J, Weitz I, et al. Pegcetacoplan versus eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med. 2021;384(11):1028–1037. doi:10.1056/NEJMoa2029073.
   PubMed Web of Science ®Google Scholar
• de Latour RP, Szer J, Weitz IC, et al. Pegcetacoplan versus eculizumab in patients with paroxysmal nocturnal haemoglobinuria (PEGASUS): 48-week follow-up of a randomised, open-label, phase 3, active-comparator, controlled trial. Lancet Haematol. 2022;9:e648–e659.
   PubMed Web of Science ®Google Scholar
• Cella D, Sarda SP, Hsieh R, et al. Changes in hemoglobin and clinical outcomes drive improvements in fatigue, quality of life, and physical function in patients with paroxysmal nocturnal hemoglobinuria: post hoc analyses from the phase III PEGASUS study. Ann Hematol. 2022;101(9):1905–1914. doi:10.1007/s00277-022-04887-8.
   PubMed Web of Science ®Google Scholar
• Bhak RH, Mody-Patel N, Baver SB, et al. Comparative effectiveness of pegcetacoplan versus ravulizumab in patients with paroxysmal nocturnal hemoglobinuria previously treated with eculizumab: a matching-adjusted indirect comparison. Curr Med Res Opin. 2021;37:1913–1923.
   PubMed Web of Science ®Google Scholar
• An open label, non-randomized, multi-center extension study to evaluate the long-term safety and efficacy of pegcetacoplan in the treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH) [Internet]. Clinicaltrials.gov. U. S. National Institutes of Health. 2023. https://www.clinicaltrials.gov/study/NCT03531255.
   Google Scholar
• An open label, single-arm, phase 2 study to evaluate the safety, pharmacokinetics, and biologic activity of pegcetacoplan in pediatric patients with paroxysmal nocturnal hemoglobinuria [Internet]. Clinicaltrials.gov. U. S. National Institutes of Health. 2023. https://www.clinicaltrials.gov/study/NCT04901936.
   Google Scholar
• Risitano AM, Frieri C, Urciuoli E, et al. The complement alternative pathway in paroxysmal nocturnal hemoglobinuria: from a pathogenic mechanism to a therapeutic target. Immunol Rev. 2023;313:262–278.
   PubMed Web of Science ®Google Scholar
• Yuan X, Gavriilaki E, Thanassi JA, et al. Small-molecule factor D inhibitors selectively block the alternative pathway of complement in paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome. Haematologica. 2017;102(3):466–475. doi:10.3324/haematol.2016.153312.
   PubMed Web of Science ®Google Scholar
• A phase 2 open-label proof of concept study to assess the efficacy, safety, and pharmacokinetics of ACH-0144471 in untreated patients with paroxysmal nocturnal hemoglobinuria [Internet]. Clinicaltrials.gov. U. S. National Institutes of Health. 2023. https://www.clinicaltrials.gov/study/NCT03053102.
   Google Scholar
• Risitano AM, Kulasekararaj AG, Lee JW, et al. Danicopan: an oral complement factor D inhibitor for paroxysmal nocturnal hemoglobinuria. Haematologica. 2020;106(12):3188–3197. Online ahe. doi:10.3324/haematol.2020.261826.
   Web of Science ®Google Scholar
• An open-label study to evaluate efficacy and safety of long-term treatment with ACH-0144471 in participants who completed clinical study ACH471-100 [Internet]. Clinicaltrials.gov. U. S. National Institutes of Health. 2023. https://www.clinicaltrials.gov/study/NCT03181633.
   Google Scholar
• A phase 2 open-label study of ACH-0144471 in patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Who have an inadequate response to eculizumab monotherapy [Internet]. Clinicaltrials.gov. U. S. National Institutes of Health. 2023. https://www.clinicaltrials.gov/study/NCT03472885.
   Google Scholar
• Kulasekararaj A, Risitano AM, Maciejewski JP, et al. A phase 2 Open-Label study of danicopan (ACH-0144471) in patients with paroxysmal nocturnal hemoglobinuria (PNH) who have an inadequate response to eculizumab monotherapy. Blood. 2019;134(Supplement_1):3514–3514. doi:10.1182/blood-2019-124748.
   Google Scholar
• Kulasekararaj AG, Risitano AM, Maciejewski JP, et al. Phase 2 study of danicopan in patients with paroxysmal nocturnal hemoglobinuria with an inadequate response to eculizumab. Blood. 2021;138(20):1928–1938. doi:10.1182/blood.2021011388.
   PubMed Web of Science ®Google Scholar
• Kulasekararaj A, Risitano A, Lee JW, et al. Phase 3 study of danicopan, an oral complement factor D inhibitor, As add-on therapy to a C5 inhibitor in patients with paroxysmal nocturnal hemoglobinuria with clinically evident extravascular hemolysis. Blood. 2020;136(Supplement 1):6–7. doi:10.1182/blood-2020-134388.
   PubMedGoogle Scholar
• A phase 3 study of danicopan (ALXN2040) as add-on therapy to a C5 inhibitor (Eculizumab or Ravulizumab) in patients with paroxysmal nocturnal hemoglobinuria who have clinically Evident Extravascular Hemolysis (EVH) [Internet]. Clinicaltrials.gov. U. S. National Institutes of Health. 2023. https://www.clinicaltrials.gov/study/NCT04469465.
   Google Scholar
• A Long-term Extension (LTE) study to characterize the safety and efficacy of danicopan as an add-on therapy to a complement component 5 inhibitor (C5i) in patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) previously treated with danicopan in an alexion-sponsored clinical study [Internet]. Clinicaltrials.gov. U. S. National Institutes of Health. 2023. https://clinicaltrials.gov/study/NCT05389449.
   Google Scholar
• Lee JW, Griffin M, Kim JS, et al. Addition of danicopan to ravulizumab or eculizumab in patients with paroxysmal nocturnal haemoglobinuria and clinically significant extravascular haemolysis (ALPHA): a double-blind, randomised, phase 3 trial. Lancet Haematol. 2023;10(12):e955–e965. doi:10.1016/S2352-3026(23)00315-0.
   PubMed Web of Science ®Google Scholar
• A phase 2 open-label proof of concept study to assess the efficacy, safety, and pharmacokinetics of the oral Factor D (FD) inhibitor ALXN2050 (ACH-0145228) in Paroxysmal Nocturnal Hemoglobinuria (PNH) patients as monotherapy [Internet]. Clinicaltrials.gov. U. S. National Institutes of Health. 2023. https://www.clinicaltrials.gov/study/NCT04170023.
   Google Scholar
• Browett PJ, Kulasekararaj A, Notaro R, et al. Vemircopan (ALXN2050) monotherapy in paroxysmal nocturnal hemoglobinuria: interim data from a phase 2 Open-Label proof-of-Concept study. Blood. 2022;140(Supplement 1):717–719. doi:10.1182/blood-2022-169301.
   Google Scholar
• Kulasekararaj A, Füreder W, McDonald A, et al. P826: factor D inhibition With oral BCX9930 leads To sustained control Of hemolysis And symptoms Over 48 weeks In subjects With paroxysmal nocturnal hemoglobinuria inadequately controlled On C5 inhibitors. Hemasphere. 2022;6:720–721. doi:10.1097/01.HS9.0000846188.51290.75.
   Google Scholar
• An open-label, multicenter, intra-subject dose escalation study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and therapeutic potential of BCX10013 in subjects with Paroxysmal Nocturnal Hemoglobinuria [Internet]. Clinicaltrials.gov. U. S. National Institutes of Health. 2023. https://www.clinicaltrials.gov/study/NCT06100900.
   Google Scholar
• Schubart A, Anderson K, Mainolfi N, et al. Small-molecule factor B inhibitor for the treatment of complement-mediated diseases. Proc Natl Acad Sci U S A. 2019;116:7926–7931.
   PubMed Web of Science ®Google Scholar
• Mainolfi N, Ehara T, Karki RG, et al. Discovery of 4-((2S,4S)-4-Ethoxy-1-((5-methoxy-7-methyl-1H-indol-4-yl)methyl)piperidin-2-yl)benzoic acid (LNP023), a factor B inhibitor specifically designed To be applicable to treating a diverse array of complement mediated diseases. J Med Chem. 2020;63:5697–5722.
   PubMed Web of Science ®Google Scholar
• An open label, single arm, multiple dose study to assess efficacy, safety, pharmacokinetics and pharmacodynamics of LNP023 when administered in addition to standard of care (soc) in patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) with signs of active hemolysis [Internet]. Clinicaltrials.gov. U. S. National Institutes of Health. 2023. https://www.clinicaltrials.gov/study/NCT03439839.
   Google Scholar
• Risitano AM, Röth A, Soret J, et al. Addition of iptacopan, an oral factor B inhibitor, to eculizumab in patients with paroxysmal nocturnal haemoglobinuria and active haemolysis: an open-label, single-arm, phase 2, proof-of-concept trial. Lancet Haematol. 2021;8(5):e344–e354. doi:10.1016/S2352-3026(21)00028-4.
   PubMed Web of Science ®Google Scholar
• A multi-center, randomized, open-label, efficacy, safety, pharmacokinetics and pharmacodynamics study, assessing multiple LNP023 doses in adult patients with paroxysmal nocturnal hemoglobinuria and active hemolysis [Internet]. Clinicaltrials.gov. U. S. National Institutes of Health. 2023. https://www.clinicaltrials.gov/study/NCT03896152.
   Google Scholar
• Jang JH, Wong L, Ko B-S, et al. Iptacopan monotherapy in patients with paroxysmal nocturnal hemoglobinuria: a 2-cohort open-label proof-of-concept study. Blood Adv. 2022;6(15):4450–4460. doi:10.1182/bloodadvances.2022006960.
   PubMed Web of Science ®Google Scholar
• A randomized, multicenter, active-comparator controlled, open-label trial to evaluate efficacy and safety of oral, twice daily LNP023 in adult patients with PNH and residual anemia, despite treatment with an intravenous anti-C5 antibody. [Internet]. Clinicaltrials.gov. U. S. National Institutes of Health. 2023. https://www.clinicaltrials.gov/study/NCT04558918.
   Google Scholar
• A multicenter, single-arm, open-label trial to evaluate efficacy and safety of oral, twice daily iptacopan in adult PNH patients who are naive to complement inhibitor therapy [Internet]. Clinicaltrials.gov. U. S. National Institutes of Health. 2023. https://www.clinicaltrials.gov/study/NCT04820530.
   Google Scholar
• An open label, multicenter Roll-over Extension Program (REP) to characterize the long-term safety and tolerability of iptacopan (LNP023) in patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) who have completed pnh phase 2 and phase3 studies with iptacopan [Internet]. Clinicaltrials.gov. U. S. National Institutes of Health. 2023. https://www.clinicaltrials.gov/study/NCT04747613.
   Google Scholar
• A multicenter, single arm, open-label trial to evaluate efficacy and safety of oral, twice daily iptacopan in adult PNH patients who have Hb ≥ 10 g/dL in response to anti-C5 antibody and switch to iptacopan [Internet]. Clinicaltrials.gov. U. S. National Institutes of Health. 2023. https://www.clinicaltrials.gov/study/NCT05630001.
   Google Scholar
• A phase II, open-label study of NM8074 in Soliris®-treated patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) [Internet]. Clinicaltrials.gov. U. S. National Institutes of Health. 2023. https://www.clinicaltrials.gov/study/NCT05646563.
   Google Scholar
• A phase II, open-label study of NM8074 in patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) [Internet]. Clinicaltrials.gov. U. S. National Institutes of Health. 2023. https://www.clinicaltrials.gov/study/NCT05646524.
   Google Scholar
• A phase II, open label, multi dose study of NM8074 in soliris-treated subjects with Paroxysmal Nocturnal Hemoglobinuria (PNH) [Internet]. Clinicaltrials.gov. U. S. National Institutes of Health. 2023. https://www.clinicaltrials.gov/study/NCT05731050.
   Google Scholar
• A phase 1, randomized, placebo-controlled, double blind single ascending dose study in healthy volunteers followed by open label treatment in patients with pnh to evaluate the safety, tolerability, PK and PD of ADX-038 [Internet]. Clinicaltrials.gov. U. S. National Institutes of Health. 2023. https://www.clinicaltrials.gov/study/NCT05876312.
   Google Scholar
• A multi-center, randomized, open-label, phase 2 study to evaluate the efficacy and safety of MY008211A tablets in adult patients with paroxysmal nocturnal hemoglobinuria and active hemolysis. Clinicaltrials.gov. U. S. National Institutes of Health. 2023. https://www.clinicaltrials.gov/study/NCT06050226.
   Google Scholar
• A multi-center, randomized, parallel, open-label clinical phase II study, to evaluate the efficacy and safety of MY008211A in adult Paroxysmal Nocturnal Hemoglobinuria (PNH) patients with signs of active hemolysis [Internet]. Clinicaltrials.gov. U. S. National Institutes of Health. 2023. https://www.clinicaltrials.gov/study/NCT06134414.
   Google Scholar
• An multicenter, randomized, open-label proof of concept study to assess the efficacy, safety of HRS-5965 in patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) [Internet]. Clinicaltrials.gov. U. S. National Institutes of Health. 2023. https://www.clinicaltrials.gov/study/NCT06051357.
   Google Scholar
• A Phase 1b proof of concept study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of OMS906 in patients with paroxysmal nocturnal hemoglobinuria [Internet]. Clinicaltrials.gov. U. S. National Institutes of Health. 2023. https://www.clinicaltrials.gov/study/NCT05889299.
   Google Scholar
• A Phase 1b proof of concept study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary efficacy of OMS906 in PNH patients with a sub-optimal response to the C5 inhibitor, ravulizumab [Internet]. Clinicaltrials.gov. U.S. National Institutes of Health. 2023. https://www.clinicaltrials.gov/study/NCT05972967.
   Google Scholar
• An Open-label, phase 2 study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of kp104 in complement inhibitor-naïve subjects with Paroxysmal Nocturnal Hemoglobinuria (PNH) [Internet]. Clinicaltrials.gov. U. S. National Institutes of Health. 2023. https://www.clinicaltrials.gov/study/NCT05476887.
   Google Scholar
• Zhang F, Han B, He G, et al. Trial in progress: an Open-Label, phase 2 study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of KP104 in complement inhibitor-naïve subjects with paroxysmal nocturnal hemoglobinuria. Blood. 2022;140(Supplement 1):11459–11460. doi:10.1182/blood-2022-159172.
   Google Scholar
• Granoff DM, Kim H, Topaz N, et al. Differential effects of therapeutic complement inhibitors on serum bactericidal activity against non-groupable meningococcal isolates recovered from patients treated with eculizumab. Haematologica. 2019;104(8):e340–e344. doi:10.3324/haematol.2018.209692.
   PubMed Web of Science ®Google Scholar